Skip to application
All calculators and tools

Preparation. Administration. Evidence.

IV Dilution &
Medication Reference

Search 255 medications, read preserved historical references, and inspect separately reviewed preparation statements. Full monograph updates remain pending.

Version 6.4Release date 2026-11-04For healthcare professionals
Back to resultsA-Z list

Medication reference

Meropenem

Monograph awaiting updateThis monograph will be updated in the future.

Jump to a section
Search DailyMed products (opens in a new tab)

Historical source. Current clinical review is incomplete. This monograph will be updated in the future.

Meropenem (merrem ®) (opens in a new tab)Original source URL: https://globalrph.com/dilution/meropenem-merrem/ | Retrieved 2026-11-04

Source dates, location and integrity

This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.

Original source URL
https://globalrph.com/dilution/meropenem-merrem/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:48:18.566295+00:00
Source location
div.post-content
Packaged content SHA-256
0064de7c1cb19330f83090e3b2eb8f7a5142bce7920ca69607554ac66e037cb5
Original response SHA-256
7f967ba5e9c5ac51020376b76c8d51c89eb5f98ff32e765e2b6c4a27a015d348
Source body SHA-256
89cd4d536d3196db10bde42aeb2c6c010977aadf07803534d30002348a20ff4c

Meropenem for Injection
[ Usual Diluents ] [ Standard Dilution ] [ Storage and Stability ]
DESCRIPTION CLINICAL PHARMACOLOGY INDICATIONS AND USAGE
CONTRAINDICATIONS PRECAUTIONS ADVERSE REACTIONS
DOSAGE AND ADMINISTRATION HOW SUPPLIED WARNINGS
PRESCRIBING HIGHLIGHTS: Please see package insert for additional information and possible updates to ensure safe and effective use of this medication. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. Please read the disclaimer carefully BEFORE accessing or using this site. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Drug UPDATES: [Drug information (pdf)]

Usual Diluents Return to article top
NS (preferred - greater stability), D5W (must be used immediately)

Standard Dilutions [Amt of drug] [Infusion vol] [Infusion rate] Return to article top
DUPLEX® Containers or dilution of powder for injection:
[ 0.5 grams] [50 ml ] [15-30 minutes]
[ 1 gram] [50 ml ] [15-30 minutes]

Bolus administration (see preparation below - powder for injection):
[ 0.5 grams] [10 ml ] [3 to 5 minutes]
[ 1 gram] [20 ml ] [3 to 5 minutes]

For Intravenous Bolus Administration
Re-constitute injection vials (500 mg and 1 gram) with sterile Water for Injection (see table 4 below). Shake to dissolve and let stand until clear.

Table 4: Volume of Sterile Water for Injection for Reconstitution of Injection Vials

Vial size Amount of Diluent Added (mL) Approximate Withdrawable Volume (mL) Approximate Average Concentration (mg/mL)
500 mg 10 10 50
1 gram 20 20 50

Stability:
DUPLEX® Containers

  • 500 mg Meropenem for Injection USP and 50 mL Sodium Chloride Injection 0.9% USP in DUPLEX® Container
  • 1 gram Meropenem for Injection USP and 50 mL Sodium Chloride Injection 0.9% USP in DUPLEX® Container

Freshly prepared solutions of Meropenem for Injection USP and Sodium Chloride Injection USP should be used. Following reconstitution (activation) in the DUPLEX® Container, the product maintains satisfactory potency for 1 hour at up to 25ºC (77ºF) or for 15 hours at up to 5ºC (41ºF). Solutions of intravenous Meropenem for Injection USP and Sodium Chloride Injection USP should not be frozen.

Meropenem injection, powder, for solution

Freshly prepared solutions of Meropenem should be used. However, re-constituted solutions of Meropenem maintain satisfactory potency under the conditions described below. Solutions of intravenous Meropenem should not be frozen.

Intravenous Bolus Administration: Meropenem injection vials re-constituted with sterile Water for Injection for bolus administration (up to 50 mg/mL of Meropenem) may be stored for up to 3 hours at up to 25°C (77°F) or for 13 hours at up to 5°C (41°F).

Intravenous Infusion Administration: Solutions prepared for infusion (Meropenem concentrations ranging from 1 mg/mL to 20 mg/mL) re-constituted with Sodium Chloride Injection 0.9% may be stored for 1 hour at up to 25°C (77°F) or 15 hours at up to 5°C (41°F).

Solutions prepared for infusion (Meropenem concentrations ranging from 1 mg/mL to 20 mg/mL) re-constituted with Dextrose Injection 5% should be used immediately.

WARNINGS Return to article top
See warnings and precautions below.

DESCRIPTION Return to article top
Description:

Meropenem for injection is a sterile, pyrogen-free, synthetic, carbapenem antibacterial drug for intravenous administration. Meropenem is (4R,5S,6S)-3- [[(3S,5S)-5-(Dimethylcarbamoyl)-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid trihydrate. Its empirical formula is C17H25N3O5S•3H2O with a molecular weight of 437.52.

Meropenem for injection is a white to pale yellow crystalline powder containing meropenem trihydrate and sodium carbonate. The constituted solution varies from colorless to yellow depending on the concentration. The pH of freshly constituted solutions is between 7.3 and 8.3. Meropenem is soluble in 5% monobasic potassium phosphate solution, sparingly soluble in water, very slightly soluble in hydrated ethanol, and practically insoluble in acetone or ether.

Meropenem for Injection USP and Sodium Chloride Injection USP is supplied as a sterile, nonpyrogenic, single-use packaged combination of meropenem (drug chamber) and 50 mL of sodium chloride (diluent) in the DUPLEX® sterile container. When reconstituted as instructed, each 1 gram Meropenem for injection in the DUPLEX® Container will deliver 1 gram of meropenem and a total sodium content of 290.2 mg (12.6 mEq). Each 500 mg Meropenem for injection in the DUPLEX® Container will deliver 500 mg of meropenem and a total sodium content of 245.1 mg (10.7 mEq) [see Dosage and Administration (2.4)]. The osmolality of the reconstituted solution of Meropenem for Injection USP and Sodium Chloride Injection USP is approximately 356 mOsmol/kg for the 500 mg dose and approximately 417 mOsmol/kg for the 1 gram dose.

The DUPLEX® Container is a flexible dual chamber container. After removing the peelable foil strip, activating the seals, and thoroughly mixing, the reconstituted drug product is hyperosmotic and is intended for single intravenous use. The product (diluent and drug) contact layer is a mixture of thermoplastic rubber and a polypropylene ethylene copolymer that contains no plasticizers.

Not made with natural rubber latex, PVC or Di(2-ethylhexyl)phthalate (DEHP).

CLINICAL PHARMACOLOGY: Return to article top
Mechanism of Action:

The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding-protein (PBP) targets. Meropenem binds to PBPs 2, 3 and 4 of Escherichia coli and Pseudomonas aeruginosa; and PBPs 1, 2 and 4 of Staphylococcus aureus. Bactericidal concentrations (defined as a 3 log10 reduction in cell counts within 12 to 24 hours) are typically 1-2 times the bacteriostatic concentrations of meropenem, with the exception of Listeria monocytogenes, against which lethal activity is not observed.

Meropenem has significant stability to hydrolysis by beta-lactamases, both penicillinases and cephalosporinases produced by Gram-positive and Gram-negative bacteria.

Meropenem does not have in-vitro activity against methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-resistant Staphylococcus epidermidis (MRSE).

Resistance
There are several mechanisms of resistance to carbapenems: 1) decreased permeability of the outer membrane of Gram-negative bacteria (due to diminished production of porins) causing reduced bacterial uptake, 2) reduced affinity of the target PBPs, 3) increased expression of efflux pump components, and 4) production of antibacterial drug-destroying enzymes (carbapenemases, metallo-beta-lactamases).

Cross-Resistance
Cross-resistance is sometimes observed with isolates resistant to other carbapenems.

Interaction with Other Antimicrobials
In vitro tests show meropenem to act synergistically with aminoglycoside antibacterial drugs against some isolates of Pseudomonas aeruginosa.

Antimicrobial Activity
Meropenem has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections [see Indications and Usage (1)].

Gram-positive bacteria

Enterococcus faecalis (vancomycin-susceptible isolates only)
Staphylococcus aureus (methicillin-susceptible isolates only)
Streptococcus agalactiae
Streptococcus pneumoniae (penicillin-susceptible isolates only)
Streptococcus pyogenes
Viridans group streptococci

Gram-negative bacteria

Escherichia coli
Haemophilus influenzae
Klebsiella pneumoniae
Neisseria meningitidis
Proteus mirabilis
Pseudomonas aeruginosa

Anaerobic bacteria

Bacteroides fragilis
Bacteroides thetaiotaomicron
Peptostreptococcus species

INDICATIONS AND USAGE Return to article top
INDICATIONS AND USAGE:

1.1 Complicated Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older requiring the full adult dose only)

Meropenem for Injection USP and Sodium Chloride Injection USP is indicated for the treatment of complicated skin and skin structure infections (cSSSI) due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species.

1.2 Complicated Intra-abdominal Infections (Adult Patients and Pediatric Patients 3 Months of age and older requiring the full adult dose only)

Meropenem for Injection USP and Sodium Chloride Injection USP is indicated for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species.

1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older requiring the full adult dose only)

Meropenem for Injection USP and Sodium Chloride Injection USP is indicated for the treatment of bacterial meningitis caused by Haemophilus influenzae, Neisseria meningitidis and penicillin-susceptible isolates of Streptococcus pneumoniae.

Meropenem has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis.

For information regarding use in pediatric patients (3 months of age and older) [see Indications and Usage (1.1), (1.2) or (1.3); Dosage and Administration (2.3), and Adverse Reactions (6.1)].

1.4 Usage

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for Injection USP and Sodium Chloride Injection USP and other antibacterial drugs, Meropenem for Injection USP and Sodium Chloride Injection USP should only be used to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

CONTRAINDICATIONS Return to article top
Contraindications:
  • Known hypersensitivity to product components or anaphylactic reactions to beta-lactams.
  • Contraindicated where the administration of sodium or chloride could be clinically detrimental.

PRECAUTIONS Return to article top
WARNINGS AND PRECAUTIONS:
  • Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactams.
  • Seizures and other adverse CNS experiences have been reported during treatment.
  • Co-administration of Meropenem for Injection with valproic acid or divalproex sodium reduces the serum concentration of valproic acid potentially increasing the risk of breakthrough seizures.
  • Clostridium difficile-associated diarrhea (ranging from mild diarrhea to fatal colitis) has been reported. Evaluate if diarrhea occurs.
  • In patients with renal dysfunction, thrombocytopenia has been observed.
  • Solutions containing sodium ions should be used with great care, if at all, in patients where the administration of sodium could be detrimental.

ADVERSE REACTIONS Return to article top
ADVERSE REACTIONS:
Most common adverse reactions (greater than or equal to 2%) are: headache, nausea, constipation, diarrhea, anemia, vomiting, and rash

See PACKAGE INSERT for PATIENT COUNSELING INFORMATION and Medication Guide. Drug information (pdf)

DOSAGE AND ADMINISTRATION Return to article top
DOSAGE AND ADMINISTRATION:
2.1 Adult Patients

Meropenem for Injection USP and Sodium Chloride Injection USP in the DUPLEX® Container should be used only in patients who require the entire 500 mg or 1 gram dose and not any fraction thereof. The recommended dose of Meropenem for Injection USP and Sodium Chloride Injection USP is 500 mg given every 8 hours for skin and skin structure infections and 1 gram given every 8 hours for intra-abdominal infections. When treating complicated skin and skin structure infections caused by P. aeruginosa, a dose of 1 gram every 8 hours is recommended.

Meropenem for Injection USP and Sodium Chloride Injection USP should be administered by intravenous infusion over approximately 15 to 30 minutes.

Additional comments for meropenem injection, powder, for solution (pdf)

Meropenem for injection (I.V.) should be administered by intravenous infusion over approximately 15 minutes to 30 minutes. Doses of 1 gram may also be administered as an intravenous bolus injection (5 mL to 20 mL) over approximately 3 minutes to 5 minutes.

2.2 Use in Adult Patients with Renal ImpairmentSeparate renal reference: Open Renal Dosing Master (opens in a new tab)

Dosage should be reduced in patients with creatinine clearance of 50 mL/min or less. (See dosing table below.)

Dosage should be reduced in renal failure if less than a full dose (1 gram or 500 mg) is required and an alternative formulation should be used to avoid risk of overdose.

When only serum creatinine is available, the following formula (Cockcroft and Gault equation)2 may be used to estimate creatinine clearance.

Males: Creatinine Clearance (mL/min) =

Weight (kg) x (140 - age)
72 x serum creatinine (mg/dL)

Females: 0.85 x above value

Table 1: Recommended Meropenem for Injection Dosage Schedule for Adult Patients With Renal Impairment

Creatinine Clearance (mL/min)Separate renal reference: Open Renal Dosing Master (opens in a new tab) Dose (dependent on type of infection) Dosing Interval
greater than 50 Recommended dose (500 mg cSSSI and 1 gram Intra-abdominal infection) Every 8 hours
26-50 Recommended dose Every 12 hours
10-25 One-half recommended dose Every 12 hours
less than 10 One-half recommended dose Every 24 hours

There is inadequate information regarding the use of meropenem for injection in patients on hemodialysis or peritoneal dialysis.

2.3 Use in Pediatric Patients (3 Months of age and older only)
  • Meropenem for Injection USP and Sodium Chloride Injection USP in the DUPLEX® Container is designed to deliver a 500 mg or 1 gram dose of meropenem. To prevent unintentional overdose, this product should not be used in pediatric patients who require less than the full adult dose of meropenem. Meropenem is not to be used in pediatric patients aged less than three months. For pediatric patients 3 months of age and older, the Meropenem for Injection USP and Sodium Chloride Injection USP dose is 10 mg/kg, 20 mg/kg or 40 mg/kg every 8 hours (maximum dose is 2 grams every 8 hours), depending on the type of infection (cSSSI, cIAI, intra-abdominal infection or meningitis). See dosing table 2 below. [see Use in Specific Populations (8.4)].
  • For pediatric patients weighing over 50 kg administer Meropenem for Injection USP and Sodium Chloride Injection USP at a dose of 500 mg every 8 hours for cSSSI, 1 gram every 8 hours for cIAI and 2 grams every 8 hours for meningitis.
  • Administer Meropenem for Injection USP and Sodium Chloride Injection USP as an intravenous infusion over approximately 15 minutes to 30 minutes.

Table 2: Recommended Meropenem for injection (I.V.) Dosage Schedule for Pediatric Patients 3 Months of Age and Older With Normal Renal Function

Type of Infection Dose (mg/kg) Up to a Maximum Dose Dosing Interval
Complicated Skin and Skin Structure Infections 10 500 mg Every 8 hours
Complicated Intra-abdominal Infections 20 1 gram Every 8 hours
Meningitis 40 2 grams Every 8 hours

There is no experience in pediatric patients with renal impairment.

When treating cSSSI caused by P. aeruginosa, a dose of 20 mg/kg (or 1 gram for pediatric patients weighing over 50 kg) every 8 hours is recommended.

2.4 Preparation and Administration of Meropenem for Injection USP and Sodium Chloride Injection USP in DUPLEX® Container

Important Administration Instructions

  • Do not use in series connections. Such use would result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is complete. If administration is controlled by a pumping device, care must be taken to discontinue pumping action before the container runs dry or air embolism may result.
  • Do not introduce additives into the DUPLEX® Container.
  • Administer Meropenem for Injection USP and Sodium Chloride Injection USP intravenously over approximately 15 to 30 minutes.

This reconstituted solution is for intravenous use only. Additional info - DUPLEX® Container

Additional comments for meropenem injection, powder, for solution (pdf)

Important Administration Instructions:

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

For Intravenous Bolus Administration

Re-constitute injection vials (500 mg and 1 gram) with sterile Water for Injection (see table 4 below). Shake to dissolve and let stand until clear.

Table 4: Volume of Sterile Water for Injection for Reconstitution of Injection Vials

Vial size

 Amount of Diluent Added (mL) Approximate Withdrawable Volume (mL) Approximate Average Concentration (mg/mL)
500 mg 10 10 50
1 gram 20 20 50

For Infusion

  • Injection vials (500 mg and 1 gram) may be directly re-constituted with a compatible infusion fluid.
  • Alternatively, an injection vial may be re-constituted, then the resulting solution added to an intravenous container and further diluted with an appropriate infusion fluid [ see Dosage and Administration (2.5) and ( 2.6)].
  • Do not use flexible container in series connections.

2.5 Compatibility

Compatibility of Meropenem for Injection USP and Sodium Chloride Injection USP with other drugs has not been established. Meropenem for Injection USP and Sodium Chloride Injection USP should not be mixed with or physically added to solutions containing other drugs.

2.6 Stability and Storage

Freshly prepared solutions of Meropenem for Injection USP and Sodium Chloride Injection USP should be used. Following reconstitution (activation) in the DUPLEX® Container, the product maintains satisfactory potency for 1 hour at up to 25ºC (77ºF) or for 15 hours at up to 5ºC (41ºF). Solutions of intravenous Meropenem for Injection USP and Sodium Chloride Injection USP should not be frozen.

Additional comments for meropenem injection, powder, for solution (pdf)

Freshly prepared solutions of Meropenem should be used. However, re-constituted solutions of Meropenem maintain satisfactory potency under the conditions described below. Solutions of intravenous Meropenem should not be frozen.

Intravenous Bolus Administration

Meropenem injection vials re-constituted with sterile Water for Injection for bolus administration (up to 50 mg/mL of Meropenem) may be stored for up to 3 hours at up to 25°C (77°F) or for 13 hours at up to 5°C (41°F).

Intravenous Infusion Administration

Solutions prepared for infusion (Meropenem concentrations ranging from 1 mg/mL to 20 mg/mL) re-constituted with Sodium Chloride Injection 0.9% may be stored for 1 hour at up to 25°C (77°F) or 15 hours at up to 5°C (41°F).

Solutions prepared for infusion (Meropenem concentrations ranging from 1 mg/mL to 20 mg/mL) re-constituted with Dextrose Injection 5% should be used immediately.

HOW SUPPLIED Return to article top
DOSAGE FORMS AND STRENGTHS:
  • 500 mg Meropenem for Injection USP and 50 mL Sodium Chloride Injection 0.9% USP in DUPLEX® Container
  • 1 gram Meropenem for Injection USP and 50 mL Sodium Chloride Injection 0.9% USP in DUPLEX® Container
  • Single dose clear glass vials of Meropenem for Injection (I.V.) containing 500 mg or 1 gram (as the trihydrate blended with anhydrous sodium carbonate for re-constitution) of sterile meropenem powder.

Storage and Stability Return to article top

DUPLEX® Container:

Meropenem for Injection USP and Sodium Chloride Injection USP in the DUPLEX® Container is a flexible dual chamber container supplied in two concentrations. The diluent chamber contains approximately 50 mL of 0.9% Sodium Chloride Injection USP. After reconstitution, the delivered doses are equivalent to 5001 mg and 11 gram meropenem.

Meropenem for Injection USP and Sodium Chloride Injection USP is supplied sterile and nonpyrogenic in the DUPLEX® Container packaged 24 units per case.

NDC REF Dose Volume
0264-3183-11 3183-11 500 mg 50 mL
0264-3185-11 3185-11 1 gram 50 mL

Store the unactivated unit at 20-25°C (68-77°F). Excursion permitted to 15-30°C. [See USP Controlled Room Temperature.] Protect from freezing.

Use only if prepared solution is clear and free from particulate matter.

------------------------
meropenem injection, powder, for solution

Meropenem for injection, USP (I.V.) is supplied in 20 mL and 30 mL injection vials containing sufficient meropenem to deliver 500 mg or 1 gram for intravenous administration, respectively. The dry powder should be stored at controlled room temperature 20º to 25ºC (68º to 77ºF) [see USP].

Product No. NDC No. Strength
PRX350725 63323-507-25 500 mg/vial Injection Vial packaged in cartons of 25
PRX350825 63323-508-25 1 g/vial Injection Vial packaged in cartons of 25

Open this historical article on its own

Product identifiers and clinical review status

This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • Retrievable exact-product SPL XML with version, revision, retrieval date and reproducible hash
  • Clinically reviewed, individually identified statements with two exact source mappings
  • Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
  • Renal-function methods and dialysis/CRRT modality review where applicable
  • Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation

Supplemental historical fields

Restored-data provenance and review notes

Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.

Current review annotations for historical renal, dialysis, mechanism, and product fieldsSeparate renal reference: Open Renal Dosing Master (opens in a new tab)
Renal
Status
not_locally_normalized
Original classification
adjustment_required
Entries
    General note
    Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
    Dialysis
    Status
    no_local_structured_regimen
    Entries
      General note
      Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
      Mechanisms
      • Source kind
        first_look
        Local pointer
        /mechanism
        Original level
        class_level
        Provenance classification
        historical_class_level
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        Not recorded
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      Future update
      Status
      pending_review
      Message
      This monograph will be updated in the future as current exact-product and claim-level review is completed.
      Source unavailable
      false
      Reason
      The historical content is restored; comprehensive contemporary verification remains incomplete.
      Historical first look: uses, mechanism, dosing context, and administration

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      meropenem
      Source IDH51-14564C67DC38AC2F7FEB1C97
      Generic name
      Meropenem
      Source IDH51-8032CC6ED7726A0435FFD998
      Class
      Antibacterial
      Source IDH51-64215BC5B44B45AB95ECED7E
      Subclass
      Carbapenem
      Source IDH51-77173BEE56BACCC6F6F5289F
      Primary uses
      1. Severe polymicrobial and resistant gram-negative infections
        Source IDH51-89616667F9AC4D7647E38878
      2. Meningitis
        Source IDH51-46B5F2582466ED12DF4CAB54
      Mechanism
      Beta-lactam binding to bacterial penicillin-binding proteins inhibits peptidoglycan cross-linking and cell-wall synthesis.
      Source IDH51-5DB22A866A61FCAE35CCAB96
      Mechanism level
      class_level
      Source IDH51-1D595EC06BAEDD78D265760C
      Basic dosing orientation
      Adult | Existing preparation record; use current package insert for indication-specific selection | Common dose 500 mg to 2 g | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion; Pediatric and neonatal | Existing preparation record; use current package insert for indication-specific selection | Weight-based dose; indication and age dependent | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion
      Source IDH51-9325EEF2B14E735776111BCE
      Administration orientation
      Infuse over 15 to 30 minutes; extended infusion often 3 hours under protocol; Infuse over 15 to 30 minutes or validated extended infusion
      Source IDH51-0195C271E195D71A8DF4A111
      Renal and population orientation
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)Renal dose adjustment or interval modification is commonly required; verify the selected product label and patient-specific renal method.
      Source IDH51-D03AAE9B1B35336A13D5AB9D
      Key safety orientation
      1. Seizure risk, especially with CNS disease or renal dysfunction.
        Source IDH51-7B4BE5534520DDEA29D56859
      2. Carbapenems can markedly reduce valproate concentrations.
        Source IDH51-73C5DB2DE9D05644CE030700
      Coverage path
      structured_local_snapshot
      Source IDH51-A2021BFEB02FED58939D82CF
      Coverage path label
      Structured GlobalRPh route snapshot
      Source IDH51-5B1DC083F7A401C38A9D72C9
      Legacy title
      Meropenem
      Source IDH51-50950932D35B2B6C0BF9DDB5
      Review note
      First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
      Source IDH51-A30C801220C7EF211F5D0890
      Search text
      Meropenem Antibacterial Carbapenem Severe polymicrobial and resistant gram-negative infections Meningitis Beta-lactam binding to bacterial penicillin-binding proteins inhibits peptidoglycan cross-linking and cell-wall synthesis. Adult | Existing preparation record; use current package insert for indication-specific selection | Common dose 500 mg to 2 g | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion; Pediatric and neonatal | Existing preparation record; use current package insert for indication-specific selection | Weight-based dose; indication and age dependent | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion Infuse over 15 to 30 minutes; extended infusion often 3 hours under protocol; Infuse over 15 to 30 minutes or validated extended infusion Renal dose adjustment or interval modification is commonly required; verify the selected product label and patient-specific renal method. Seizure risk, especially with CNS disease or renal dysfunction. Carbapenems can markedly reduce valproate concentrations. Structured GlobalRPh route snapshot
      Source IDH51-F90E574DD5C7E8719B615814
      Official access mode
      search
      Source IDH51-76C25CBB2F67988883FB8171
      Official search query
      Meropenem
      Source IDH51-A114779BE4710FE048521361
      Official access reason
      A source-backed DailyMed search is available; select and confirm the exact IV product.
      Source IDH51-D9D1A6D1A6FB1720E480C4BA

      No separate structured rows were bundled for IV push, continuous infusion, dialysis, CRRT. Historical article content and source links may cover these topics.

      Historical dilution and intermittent infusion preparation

      Recovered v5.1 source content; historical, awaiting current review.

      PopulationAmountReconstitutionDiluentFinal volumeConcentrationRateStabilityNotes
      Source IDH51-DE6EB6BA91753C9F01D9615D
      Adult
      Source IDH51-97E3CCD17CA9CD9428D6EFFB
      		Common dose 500 mg to 2 g
      Source IDH51-7B4B39803CD3DDC6A079B938
      		Reconstitute vial with Sterile Water for Injection or label-compatible fluid.
      Source IDH51-D86CC7D6689A0005F8E35085
      		NS commonly preferred; D5W stability is shorter
      Source IDH51-313D5A8E5091C873506A5924
      		50 to 100 mL
      Source IDH51-3AF89C9E18BD7F52EB9DD643
      		Commonly 10 to 20 mg/mL
      Source IDH51-1D5F374A7CDC9D3F001F611A
      		Infuse over 15 to 30 minutes; extended infusion often 3 hours under protocol
      Source IDH51-F0E51547C0CC240AAB16EB8D
      		Use the shorter of current product labeling, validated stability data, and the applicable USP <797> sterility-based BUD ceiling.
      Source IDH51-30498ACF34495B605CF8B559
      		Solution stability is temperature, concentration, and diluent dependent; prepare close to administration when possible.
      Source IDH51-41D394ACF9B9BC5391C5A6B0
      Source IDH51-E353B494786F4A79600A7972
      Pediatric and neonatal
      Source IDH51-5389AB52C2504C216BEB1FE1
      		Weight-based dose; indication and age dependent
      Source IDH51-C63515ABA1472FC551B9B7F5
      		Reconstitute per vial labeling.
      Source IDH51-84E17D3FABBE80B9DDFECBA8
      		Compatible fluid
      Source IDH51-7ACE3C3F3702BC1EA7D61F57
      		Weight-appropriate volume
      Source IDH51-275F4D8EE908F1FE7D24A7B1
      		Institution-specific
      Source IDH51-FB3109281C4D18216EEEB5E4
      		Infuse over 15 to 30 minutes or validated extended infusion
      Source IDH51-CE93DCA6003CAA1000039E77
      		Use the shorter of current product labeling, validated stability data, and the applicable USP <797> sterility-based BUD ceiling.
      Source IDH51-8ECE27293A06196FF591D524

      Historical indication and population dosing

      Recovered tables and source-separated snapshots; full clinical revalidation remains pending.

      Existing dose and route snapshots

      RoutePopulationIndicationDoseIntervalDurationAdministrationSource levelNotes
      Source IDH51-A0953BE4A378A0A041B9E665
      IV infusion
      Source IDH51-003D2F9932A88FFC37F5827D
      		Adult
      Source IDH51-B935D8AF6CEAD727E6A1EF06
      		Existing preparation record; use current package insert for indication-specific selection
      Source IDH51-6773756DD38465030B41FB63
      		Common dose 500 mg to 2 g
      Source IDH51-BFDB0C1576992E3BBBDB01F5
      		Not normalized in the preparation record
      Source IDH51-A3F13B9378271B34804DC097
      		See current package insert and professional guidance
      Source IDH51-BDABFFC83E9698F9FEDCEB95
      		Infuse over 15 to 30 minutes; extended infusion often 3 hours under protocol
      Source IDH51-60877EC6567F3422DDC9C852
      		Existing GlobalRPh structured preparation snapshot
      Source IDH51-96E523011244006F5B55AA08
      		Solution stability is temperature, concentration, and diluent dependent; prepare close to administration when possible.
      Source IDH51-58C76635076930F14EEA0C7A
      Source IDH51-A8F2EF73BADDF26FC6C15F6C
      IV infusion
      Source IDH51-8D2F5E127A02DCBCE1C478B0
      		Pediatric and neonatal
      Source IDH51-BD32F698642D652B62F16409
      		Existing preparation record; use current package insert for indication-specific selection
      Source IDH51-13FA199A91DFF39250878D8A
      		Weight-based dose; indication and age dependent
      Source IDH51-5EFCBB7C2B5FA7F329031B70
      		Not normalized in the preparation record
      Source IDH51-7FB1932D24941A6A8F255FE3
      		See current package insert and professional guidance
      Source IDH51-E38B6873611F4AFE1E07AFED
      		Infuse over 15 to 30 minutes or validated extended infusion
      Source IDH51-87ED98DD6A502CDF4D7F6173
      		Existing GlobalRPh structured preparation snapshot
      Source IDH51-D3AA1A7DD45C17A6D204DC31

      Historical renal-function guidance

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      Classification
      adjustment_required
      Source IDH51-42847E6034CA0958355C69F9
      Summary
      Renal dose adjustment or interval modification is commonly required; verify the selected product label and patient-specific renal method.
      Source IDH51-574E9C0FCAFB826862451248
      Method note
      Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
      Source IDH51-C6916C1DAF2F2D38EE1BF3BB

      Historical Common IV uses

      Recovered v5.1 source content; historical, awaiting current review.

      1. Severe polymicrobial and resistant gram-negative infections
        Source IDH51-D2A31CD142CAD77E8E214E7A
      2. Meningitis
        Source IDH51-F5C476CCF502ED9677DEA072

      Historical Warnings and safeguards

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      1. Seizure risk, especially with CNS disease or renal dysfunction.
        Source IDH51-843FF19D078BF66695A77317
      2. Carbapenems can markedly reduce valproate concentrations.
        Source IDH51-BDC81265F830D1F7BC9F4CBD

      Historical Monitoring

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      1. Renal function
        Source IDH51-2FA33719440D6C4B12B319DB
      2. Neurologic status
        Source IDH51-21D4F6806707B69D2A742058
      3. Clinical and microbiologic response
        Source IDH51-0B80197F4E2AE35CC13223D3

      Historical supplemental professional sources

      Recovered v5.1 source content; historical, awaiting current review.

      LabelUrlKind
      Source IDH51-B1241A02A8DA23179E3EDF26
      UCSF adult antimicrobial dosing, non-dialysis
      Source IDH51-4A8ED03DDA0A0410769B939F
      		https://idmp.ucsf.edu/adult-antimicrobial-dosing-non-dialysis (opens in a new tab)
      Source IDH51-5C5B5C60F8483E1174B9CB9D
      		Professional institutional guidance
      Source IDH51-05763AD3C5E8FFE7979E0050
      Source IDH51-C872FE560691E87BB783E82F
      UCSF antimicrobial dosing in intermittent and continuous hemodialysis
      Source IDH51-0F38082A91A4EBBCA5504414
      		https://idmp.ucsf.edu/antimicrobial-dosing-intermittent-continuous-hemodialysis (opens in a new tab)
      Source IDH51-41DC1B13601835BB7602AAEF
      		Professional institutional guidance
      Source IDH51-4CBA676D737C8C093EB46DB8
      Source IDH51-126840F175E3D1C0FE6E31CD
      UCSF pediatric antimicrobial dosing
      Source IDH51-C4C2F496D5EE22FFF9C303B4
      		https://idmp.ucsf.edu/pediatric-antimicrobial-dosing-benioff-childrens-hospitals (opens in a new tab)
      Source IDH51-C86DB7501A294733DAFCD81D
      		Professional institutional guidance
      Source IDH51-2781DEF6AA9CBF391C026CF2
      Source IDH51-5F80229B0C0AC71F2167CADD
      UCSF neonatal antimicrobial dosing
      Source IDH51-8FAFF3D554C7F7FF75BEEA78
      		https://idmp.ucsf.edu/neonatal-antimicrobial-dosing-benioff-childrens-hospitals (opens in a new tab)
      Source IDH51-C520EC2F982FACD6243F4B64
      		Professional institutional guidance
      Source IDH51-9381E551E7125EC55DEFC3E0
      Other recovered source fields and original editorial metadata

      Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.

      Catalog source fields

      Id
      meropenem
      Source IDH51-574B14D288BE4D7D819CABB4
      Generic name
      Meropenem
      Source IDH51-C09E5AA0E03F89FEC84A4ED7
      Brand names
      1. Merrem
        Source IDH51-A5E7837A09E17F0BE92BAC33
      Class
      Antibacterial
      Source IDH51-B843AA4AA22DFEF005681D6A
      Subclass
      Carbapenem
      Source IDH51-21BC695C246158F1CAA83F4F
      Summary
      Broad-spectrum carbapenem commonly administered as a 15- to 30-minute infusion or by validated extended-infusion protocol.
      Source IDH51-6579B811E4DE721E422B6E33
      Populations
      1. Adult
        Source IDH51-DF22A7AECCDEF376FE96D309
      2. Pediatric
        Source IDH51-2668EB2042BBB6B9A8D6DE64
      3. Neonatal
        Source IDH51-4DD362382DC94E856E6D31E4
      Evidence tier
      Core reference - verify current label
      Source IDH51-C3C60F6EA9CCD4CDD1DAFEE5
      High alert
      true
      Source IDH51-680452F734F0F84FF593C442
      Hazardous
      false
      Source IDH51-896C86DEE75FB825D65C8D6C
      Status
      Active
      Source IDH51-1DC8D9F10205F74099028BF7
      Reviewed
      2026-08-29
      Source IDH51-24B525489697702971550648
      Version added
      1.0
      Source IDH51-95194D10DFA3C179C95C8B32
      Sources
      LabelUrlKind
      Source IDH51-ABDF51977A429282C4B39370
      DailyMed label search
      Source IDH51-F8947704C6F3D499A7A740FD
      		https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Meropenem (opens in a new tab)
      Source IDH51-ACF40530E8FB2FCDEB2D9C84
      		Primary
      Source IDH51-2912F9AEA44F4805A0325107
      Source IDH51-63C92A8CB4CF3C9126D66997
      GlobalRPh legacy IV dilution monograph
      Source IDH51-25028F92704A0DD7364F80E5
      		legacy:auto
      Source IDH51-7E1CCB378792777BE9461508
      		Legacy
      Source IDH51-2AC578EA5309D6F814246555
      Legacy title
      Meropenem
      Source IDH51-2D43F7BE71444DF5B39EF1E9
      Clinical release verification
      Audit version
      3.4
      Source IDH51-A0E4C596473A460C783D9E4C
      Audited on
      2026-08-30
      Source IDH51-C07B6484742CDFB29E858996
      Level
      amber
      Source IDH51-29475CF207C35327416DA211
      Release gate
      trusted_professional_source_present_exact_label_unconfirmed
      Source IDH51-0D8D9926559411EB6CAA7C7E
      Exact current label candidate
      false
      Source IDH51-8B98CC07B0433458B86A28F3
      Numeric support ratio
      0
      Source IDH51-91B05DB6667E7D936A334A28
      Reference url count
      5
      Source IDH51-A8886A97058D28011FD19950
      Broken reference count
      0
      Source IDH51-55E886804F24AA70BF86F7ED
      Point of use confirmation required
      true
      Source IDH51-9FEB712095196119FB1908BB
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-D6A99569D089B26C4BDDEE18

      Dosing source fields

      Id
      meropenem
      Source IDH51-3A707DBFC828AB8BA359482D
      Generic name
      Meropenem
      Source IDH51-2F6D2A4893E92F76B9709CBB
      Coverage status
      direct_official_label_access_plus_local_snapshot
      Source IDH51-2C7C142B700A0E826A15065F
      Package insert
      Query name
      Meropenem
      Source IDH51-D73F11D66F6B64A6FAAA54BA
      Product and route must match
      true
      Source IDH51-02B840E94438ACFECB2F3845
      Live current label enabled
      false
      Source IDH51-8D3767A9FD4C7B1F20244D69
      Source priority
      Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
      Source IDH51-5C18CB6AD1855C15E570E381
      Direct official label access enabled
      true
      Source IDH51-707D14E001A76FC2696B801C
      Outbound server request required
      false
      Source IDH51-DE4038DF4DD969B59B0FF64A
      Local summary status
      not_bundled
      Source IDH51-027732860495892FC6EAF4B0
      Clinical review
      Locally normalized
      false
      Source IDH51-A131E8CD90FD2C35C8F6FD52
      Reviewed
      2026-08-29
      Source IDH51-62EC523A3326550CF50C0440
      Status
      Direct official package-insert access enabled; indication-specific local normalization pending.
      Source IDH51-39DA7DAAF17DCA43595E1670
      Clinical release verification
      Audit version
      3.4
      Source IDH51-A371BF7D99FC397C44F4DB1C
      Audited on
      2026-08-30
      Source IDH51-B8B5470E28B2564475798780
      Level
      amber
      Source IDH51-0DA5671ACDD2E5456BDD257C
      Release gate
      trusted_professional_source_present_exact_label_unconfirmed
      Source IDH51-219A88082FC350D05DA3BD8E
      Exact current label candidate
      false
      Source IDH51-DD0010D871FDB829D3801FD5
      Numeric support ratio
      0
      Source IDH51-2279316AA910BA67405DD050
      Reference url count
      5
      Source IDH51-068878B44EDC5E08FE0CC121
      Broken reference count
      0
      Source IDH51-0EFD1945C099D679CF5EAE45
      Point of use confirmation required
      true
      Source IDH51-1D50A7092B7CFBF00297D16D
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-D0F8BA4AC1FCDAA834614D7E
      Historical preparation assessment

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      meropenem
      Source IDH51-DF92A74FF7E8A1F174FCF997
      Name
      Meropenem
      Source IDH51-C2254A67F572F72C4BC10E9A
      Brands
      Merrem
      Source IDH51-AD89DAA913BB4C8CF50295B9
      Therapeutic class
      Antibacterial
      Source IDH51-5A9BBCC311AB26D64D3D54AB
      Review version
      3.1
      Source IDH51-3067DCD6B1BA9AF81AD27BC9
      Review date
      2026-08-30
      Source IDH51-8C411FC2EE9F3E499E3F1D17
      Release status
      structured_record_current_label_not_confirmed
      Source IDH51-982A4825A90C6B15A8E8544A
      Market status
      Status
      no_current_us_iv_spl_confirmed
      Source IDH51-24BAF35D8AAB8FC853237FA2
      Basis
      No high-confidence current IV SPL was automatically selected; legacy information is segregated
      Source IDH51-003F8B12D18D7373243167AB
      Ten point assessment
      Exact formulation
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-98B1D9458F988E71434A172E
      Reconstitution concentration
      Reconstitute vial with Sterile Water for Injection or label-compatible fluid. Reconstitute per vial labeling.
      Source IDH51-6D2FE7323FA3D31BD8EBBE96
      Maximum or recommended final concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-1EF8FB5A8638F198D392AF7F
      Appropriate standardized containers
      50 to 100 mL Weight-appropriate volume
      Source IDH51-23ECAF8F8526DCDBA1423537
      Adult dosing range
      Common dose 500 mg to 2 g Weight-based dose; indication and age dependent
      Source IDH51-742C0EEA4388B7207F3CA936
      Pediatric dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-B4BC570705A2E6EBB7F76ED7
      Neonatal dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-CD7D4ECBBFF2EC1F93AA84A3
      Infusion time
      Infuse over 15 to 30 minutes; extended infusion often 3 hours under protocol Infuse over 15 to 30 minutes or validated extended infusion
      Source IDH51-F5CECB8C148A454B1E47D4A9
      Fluid restriction alternatives
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-0C933837B15351D36D55DBFE
      Current manufacturer labeling
      Match confidence
      unresolved
      Source IDH51-BD72C318723EBA3C80F1B9F7
      Field provenance
      Exact formulation
      Primary
      not_found
      Source IDH51-1B2FBEC95E9023E9514F2CF8
      Reconstitution concentration
      Primary
      existing_structured_record
      Source IDH51-C0C4839EEC3CBBECB29F5E33
      Maximum or recommended final concentration
      Primary
      not_found
      Source IDH51-CE1D95C241C4782644594A88
      Appropriate standardized containers
      Primary
      existing_structured_record
      Source IDH51-9AB5E8E09EF7C2DB5003FFFF
      Adult dosing range
      Primary
      existing_structured_record
      Source IDH51-EF396E11E61C870FDDDBF689
      Pediatric dosing range
      Primary
      not_found
      Source IDH51-C4982C228B3B5BF8687AAC53
      Neonatal dosing range
      Primary
      not_found
      Source IDH51-6A7DA224F10A3E0921024D20
      Infusion time
      Primary
      existing_structured_record
      Source IDH51-31FAE08A16EC4CAFC60CB950
      Fluid restriction alternatives
      Primary
      not_found
      Source IDH51-3121121914425918D461D772
      Current manufacturer labeling
      Primary
      DailyMed search gateway
      Source IDH51-B790DFC341587D5D62E9D831
      Population applicability
      Adult
      Applicability
      supported_or_source_present
      Source IDH51-25B43E42AA8CD29AABC15BF5
      Guide generation allowed
      true
      Source IDH51-F48950553D0771FE5CFABEC8
      Pediatric
      Applicability
      supported_or_source_present
      Source IDH51-2E1B687CD03A4A3588B3D615
      Guide generation allowed
      false
      Source IDH51-73876D7451C81656F12B0958
      Neonatal
      Applicability
      supported_or_source_present
      Source IDH51-82580F8EF3F0EB451714AF5C
      Guide generation allowed
      false
      Source IDH51-B3DC748C877C7B7B38F267EE
      Route presence
      Structured dilution
      true
      Source IDH51-2898240A4F62142D7CE7247F
      Iv push
      false
      Source IDH51-78F0B4EF926BEB5B5A4FE60A
      Continuous infusion
      false
      Source IDH51-27A043CAE884B314C3085C75
      Pediatric source
      true
      Source IDH51-0EC2452B11CE361EDE2AC236
      Neonatal source
      true
      Source IDH51-350B91A44DB0E1309228348C
      Legacy reference
      Status
      not_available
      Source IDH51-CB27435D85D724CF811F1024
      Label resolution
      Status
      build_environment_network_unavailable
      Source IDH51-8EF628E132BC5F27496621E3
      Source files
      1. catalog.json
        Source IDH51-83245BA85F12FE2167753157
      2. dosing.json
        Source IDH51-6CD4F33BA534365204177BC5
      3. legacy-map.json
        Source IDH51-2510E4F5E2A9E0E7D26FF761
      Clinical release note
      Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.
      Source IDH51-981B38C88E2623EDCEB49C29
      Historical statement IDs and source locations

      These IDs identify recovered source units. They are not evidence-qualified clinical claims.

      Historical IDOriginal source locationStatus
      H51-574B14D288BE4D7D819CABB4catalog.json
      /records/157/id      		Historical; current review incomplete
      H51-C09E5AA0E03F89FEC84A4ED7catalog.json
      /records/157/generic_name      		Historical; current review incomplete
      H51-A5E7837A09E17F0BE92BAC33catalog.json
      /records/157/brand_names/0      		Historical; current review incomplete
      H51-B843AA4AA22DFEF005681D6Acatalog.json
      /records/157/class      		Historical; current review incomplete
      H51-21BC695C246158F1CAA83F4Fcatalog.json
      /records/157/subclass      		Historical; current review incomplete
      H51-6579B811E4DE721E422B6E33catalog.json
      /records/157/summary      		Historical; current review incomplete
      H51-D2A31CD142CAD77E8E214E7Acatalog.json
      /records/157/common_uses/0      		Historical; current review incomplete
      H51-F5C476CCF502ED9677DEA072catalog.json
      /records/157/common_uses/1      		Historical; current review incomplete
      H51-DE6EB6BA91753C9F01D9615Dcatalog.json
      /records/157/preparations/0      		Historical; current review incomplete
      H51-97E3CCD17CA9CD9428D6EFFBcatalog.json
      /records/157/preparations/0/population      		Historical; current review incomplete
      H51-7B4B39803CD3DDC6A079B938catalog.json
      /records/157/preparations/0/amount      		Historical; current review incomplete
      H51-D86CC7D6689A0005F8E35085catalog.json
      /records/157/preparations/0/reconstitution      		Historical; current review incomplete
      H51-313D5A8E5091C873506A5924catalog.json
      /records/157/preparations/0/diluent      		Historical; current review incomplete
      H51-3AF89C9E18BD7F52EB9DD643catalog.json
      /records/157/preparations/0/final_volume      		Historical; current review incomplete
      H51-1D5F374A7CDC9D3F001F611Acatalog.json
      /records/157/preparations/0/concentration      		Historical; current review incomplete
      H51-F0E51547C0CC240AAB16EB8Dcatalog.json
      /records/157/preparations/0/rate      		Historical; current review incomplete
      H51-30498ACF34495B605CF8B559catalog.json
      /records/157/preparations/0/stability      		Historical; current review incomplete
      H51-41D394ACF9B9BC5391C5A6B0catalog.json
      /records/157/preparations/0/notes      		Historical; current review incomplete
      H51-E353B494786F4A79600A7972catalog.json
      /records/157/preparations/1      		Historical; current review incomplete
      H51-5389AB52C2504C216BEB1FE1catalog.json
      /records/157/preparations/1/population      		Historical; current review incomplete
      H51-C63515ABA1472FC551B9B7F5catalog.json
      /records/157/preparations/1/amount      		Historical; current review incomplete
      H51-84E17D3FABBE80B9DDFECBA8catalog.json
      /records/157/preparations/1/reconstitution      		Historical; current review incomplete
      H51-7ACE3C3F3702BC1EA7D61F57catalog.json
      /records/157/preparations/1/diluent      		Historical; current review incomplete
      H51-275F4D8EE908F1FE7D24A7B1catalog.json
      /records/157/preparations/1/final_volume      		Historical; current review incomplete
      H51-FB3109281C4D18216EEEB5E4catalog.json
      /records/157/preparations/1/concentration      		Historical; current review incomplete
      H51-CE93DCA6003CAA1000039E77catalog.json
      /records/157/preparations/1/rate      		Historical; current review incomplete
      H51-8ECE27293A06196FF591D524catalog.json
      /records/157/preparations/1/stability      		Historical; current review incomplete
      H51-3AB543B24D8C65A209E4FB4Dcatalog.json
      /records/157/preparations/1/notes      		Historical; current review incomplete
      H51-843FF19D078BF66695A77317catalog.json
      /records/157/warnings/0      		Historical; current review incomplete
      H51-BDC81265F830D1F7BC9F4CBDcatalog.json
      /records/157/warnings/1      		Historical; current review incomplete
      H51-2FA33719440D6C4B12B319DBcatalog.json
      /records/157/monitoring/0      		Historical; current review incomplete
      H51-21D4F6806707B69D2A742058catalog.json
      /records/157/monitoring/1      		Historical; current review incomplete
      H51-0B80197F4E2AE35CC13223D3catalog.json
      /records/157/monitoring/2      		Historical; current review incomplete
      H51-DF22A7AECCDEF376FE96D309catalog.json
      /records/157/populations/0      		Historical; current review incomplete
      H51-2668EB2042BBB6B9A8D6DE64catalog.json
      /records/157/populations/1      		Historical; current review incomplete
      H51-4DD362382DC94E856E6D31E4catalog.json
      /records/157/populations/2      		Historical; current review incomplete
      H51-C3C60F6EA9CCD4CDD1DAFEE5catalog.json
      /records/157/evidence_tier      		Historical; current review incomplete
      H51-680452F734F0F84FF593C442catalog.json
      /records/157/high_alert      		Historical; current review incomplete
      H51-896C86DEE75FB825D65C8D6Ccatalog.json
      /records/157/hazardous      		Historical; current review incomplete
      H51-1DC8D9F10205F74099028BF7catalog.json
      /records/157/status      		Historical; current review incomplete
      H51-24B525489697702971550648catalog.json
      /records/157/reviewed      		Historical; current review incomplete
      H51-95194D10DFA3C179C95C8B32catalog.json
      /records/157/version_added      		Historical; current review incomplete
      H51-ABDF51977A429282C4B39370catalog.json
      /records/157/sources/0      		Historical; current review incomplete
      H51-F8947704C6F3D499A7A740FDcatalog.json
      /records/157/sources/0/label      		Historical; current review incomplete
      H51-ACF40530E8FB2FCDEB2D9C84catalog.json
      /records/157/sources/0/url      		Historical; current review incomplete
      H51-2912F9AEA44F4805A0325107catalog.json
      /records/157/sources/0/kind      		Historical; current review incomplete
      H51-63C92A8CB4CF3C9126D66997catalog.json
      /records/157/sources/1      		Historical; current review incomplete
      H51-25028F92704A0DD7364F80E5catalog.json
      /records/157/sources/1/label      		Historical; current review incomplete
      H51-7E1CCB378792777BE9461508catalog.json
      /records/157/sources/1/url      		Historical; current review incomplete
      H51-2AC578EA5309D6F814246555catalog.json
      /records/157/sources/1/kind      		Historical; current review incomplete
      H51-2D43F7BE71444DF5B39EF1E9catalog.json
      /records/157/legacy_title      		Historical; current review incomplete
      H51-A0E4C596473A460C783D9E4Ccatalog.json
      /records/157/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-C07B6484742CDFB29E858996catalog.json
      /records/157/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-29475CF207C35327416DA211catalog.json
      /records/157/clinical_release_verification/level      		Historical; current review incomplete
      H51-0D8D9926559411EB6CAA7C7Ecatalog.json
      /records/157/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-8B98CC07B0433458B86A28F3catalog.json
      /records/157/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-02B5362D5AADC95F8B269034catalog.json
      /records/157/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-0C284C0CB5FAE1B294684A84catalog.json
      /records/157/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-91B05DB6667E7D936A334A28catalog.json
      /records/157/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-A8886A97058D28011FD19950catalog.json
      /records/157/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-55E886804F24AA70BF86F7EDcatalog.json
      /records/157/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-9FEB712095196119FB1908BBcatalog.json
      /records/157/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-D6A99569D089B26C4BDDEE18catalog.json
      /records/157/clinical_release_verification/note      		Historical; current review incomplete
      H51-D33386A39AF1F84A34F7CBE4catalog.json
      /records/157/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-3A707DBFC828AB8BA359482Ddosing.json
      /records/157/id      		Historical; current review incomplete
      H51-2F6D2A4893E92F76B9709CBBdosing.json
      /records/157/generic_name      		Historical; current review incomplete
      H51-2C7C142B700A0E826A15065Fdosing.json
      /records/157/coverage_status      		Historical; current review incomplete
      H51-D73F11D66F6B64A6FAAA54BAdosing.json
      /records/157/package_insert/query_name      		Historical; current review incomplete
      H51-17F0440AB03CB581A60C74BBdosing.json
      /records/157/package_insert/preferred_setid      		Historical; current review incomplete
      H51-02B840E94438ACFECB2F3845dosing.json
      /records/157/package_insert/product_and_route_must_match      		Historical; current review incomplete
      H51-8D3767A9FD4C7B1F20244D69dosing.json
      /records/157/package_insert/live_current_label_enabled      		Historical; current review incomplete
      H51-5C18CB6AD1855C15E570E381dosing.json
      /records/157/package_insert/source_priority      		Historical; current review incomplete
      H51-707D14E001A76FC2696B801Cdosing.json
      /records/157/package_insert/direct_official_label_access_enabled      		Historical; current review incomplete
      H51-DE4038DF4DD969B59B0FF64Adosing.json
      /records/157/package_insert/outbound_server_request_required      		Historical; current review incomplete
      H51-027732860495892FC6EAF4B0dosing.json
      /records/157/package_insert/local_summary_status      		Historical; current review incomplete
      H51-42847E6034CA0958355C69F9dosing.json
      /records/157/renal/classification      		Historical; current review incomplete
      H51-574E9C0FCAFB826862451248dosing.json
      /records/157/renal/summary      		Historical; current review incomplete
      H51-C6916C1DAF2F2D38EE1BF3BBdosing.json
      /records/157/renal/method_note      		Historical; current review incomplete
      H51-A0953BE4A378A0A041B9E665dosing.json
      /records/157/existing_route_snapshots/0      		Historical; current review incomplete
      H51-003D2F9932A88FFC37F5827Ddosing.json
      /records/157/existing_route_snapshots/0/route      		Historical; current review incomplete
      H51-B935D8AF6CEAD727E6A1EF06dosing.json
      /records/157/existing_route_snapshots/0/population      		Historical; current review incomplete
      H51-6773756DD38465030B41FB63dosing.json
      /records/157/existing_route_snapshots/0/indication      		Historical; current review incomplete
      H51-BFDB0C1576992E3BBBDB01F5dosing.json
      /records/157/existing_route_snapshots/0/dose      		Historical; current review incomplete
      H51-A3F13B9378271B34804DC097dosing.json
      /records/157/existing_route_snapshots/0/interval      		Historical; current review incomplete
      H51-BDABFFC83E9698F9FEDCEB95dosing.json
      /records/157/existing_route_snapshots/0/duration      		Historical; current review incomplete
      H51-60877EC6567F3422DDC9C852dosing.json
      /records/157/existing_route_snapshots/0/administration      		Historical; current review incomplete
      H51-96E523011244006F5B55AA08dosing.json
      /records/157/existing_route_snapshots/0/source_level      		Historical; current review incomplete
      H51-58C76635076930F14EEA0C7Adosing.json
      /records/157/existing_route_snapshots/0/notes      		Historical; current review incomplete
      H51-A8F2EF73BADDF26FC6C15F6Cdosing.json
      /records/157/existing_route_snapshots/1      		Historical; current review incomplete
      H51-8D2F5E127A02DCBCE1C478B0dosing.json
      /records/157/existing_route_snapshots/1/route      		Historical; current review incomplete
      H51-BD32F698642D652B62F16409dosing.json
      /records/157/existing_route_snapshots/1/population      		Historical; current review incomplete
      H51-13FA199A91DFF39250878D8Adosing.json
      /records/157/existing_route_snapshots/1/indication      		Historical; current review incomplete
      H51-5EFCBB7C2B5FA7F329031B70dosing.json
      /records/157/existing_route_snapshots/1/dose      		Historical; current review incomplete
      H51-7FB1932D24941A6A8F255FE3dosing.json
      /records/157/existing_route_snapshots/1/interval      		Historical; current review incomplete
      H51-E38B6873611F4AFE1E07AFEDdosing.json
      /records/157/existing_route_snapshots/1/duration      		Historical; current review incomplete
      H51-87ED98DD6A502CDF4D7F6173dosing.json
      /records/157/existing_route_snapshots/1/administration      		Historical; current review incomplete
      H51-D3AA1A7DD45C17A6D204DC31dosing.json
      /records/157/existing_route_snapshots/1/source_level      		Historical; current review incomplete
      H51-A336739ACB423C8D01B7B8DFdosing.json
      /records/157/existing_route_snapshots/1/notes      		Historical; current review incomplete
      H51-B1241A02A8DA23179E3EDF26dosing.json
      /records/157/professional_sources/0      		Historical; current review incomplete
      H51-4A8ED03DDA0A0410769B939Fdosing.json
      /records/157/professional_sources/0/label      		Historical; current review incomplete
      H51-5C5B5C60F8483E1174B9CB9Ddosing.json
      /records/157/professional_sources/0/url      		Historical; current review incomplete
      H51-05763AD3C5E8FFE7979E0050dosing.json
      /records/157/professional_sources/0/kind      		Historical; current review incomplete
      H51-C872FE560691E87BB783E82Fdosing.json
      /records/157/professional_sources/1      		Historical; current review incomplete
      H51-0F38082A91A4EBBCA5504414dosing.json
      /records/157/professional_sources/1/label      		Historical; current review incomplete
      H51-41DC1B13601835BB7602AAEFdosing.json
      /records/157/professional_sources/1/url      		Historical; current review incomplete
      H51-4CBA676D737C8C093EB46DB8dosing.json
      /records/157/professional_sources/1/kind      		Historical; current review incomplete
      H51-126840F175E3D1C0FE6E31CDdosing.json
      /records/157/professional_sources/2      		Historical; current review incomplete
      H51-C4C2F496D5EE22FFF9C303B4dosing.json
      /records/157/professional_sources/2/label      		Historical; current review incomplete
      H51-C86DB7501A294733DAFCD81Ddosing.json
      /records/157/professional_sources/2/url      		Historical; current review incomplete
      H51-2781DEF6AA9CBF391C026CF2dosing.json
      /records/157/professional_sources/2/kind      		Historical; current review incomplete
      H51-5F80229B0C0AC71F2167CADDdosing.json
      /records/157/professional_sources/3      		Historical; current review incomplete
      H51-8FAFF3D554C7F7FF75BEEA78dosing.json
      /records/157/professional_sources/3/label      		Historical; current review incomplete
      H51-C520EC2F982FACD6243F4B64dosing.json
      /records/157/professional_sources/3/url      		Historical; current review incomplete
      H51-9381E551E7125EC55DEFC3E0dosing.json
      /records/157/professional_sources/3/kind      		Historical; current review incomplete
      H51-A131E8CD90FD2C35C8F6FD52dosing.json
      /records/157/clinical_review/locally_normalized      		Historical; current review incomplete
      H51-62EC523A3326550CF50C0440dosing.json
      /records/157/clinical_review/reviewed      		Historical; current review incomplete
      H51-39DA7DAAF17DCA43595E1670dosing.json
      /records/157/clinical_review/status      		Historical; current review incomplete
      H51-A371BF7D99FC397C44F4DB1Cdosing.json
      /records/157/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-B8B5470E28B2564475798780dosing.json
      /records/157/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-0DA5671ACDD2E5456BDD257Cdosing.json
      /records/157/clinical_release_verification/level      		Historical; current review incomplete
      H51-219A88082FC350D05DA3BD8Edosing.json
      /records/157/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-DD0010D871FDB829D3801FD5dosing.json
      /records/157/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-154E53ACDBAC978D6C03DC53dosing.json
      /records/157/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-288050C8842C424FBD188A16dosing.json
      /records/157/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-2279316AA910BA67405DD050dosing.json
      /records/157/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-068878B44EDC5E08FE0CC121dosing.json
      /records/157/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-0EFD1945C099D679CF5EAE45dosing.json
      /records/157/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-1D50A7092B7CFBF00297D16Ddosing.json
      /records/157/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-D0F8BA4AC1FCDAA834614D7Edosing.json
      /records/157/clinical_release_verification/note      		Historical; current review incomplete
      H51-900305CEECF356EF6C422F91dosing.json
      /records/157/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-14564C67DC38AC2F7FEB1C97first-look-v5.1.json
      /records/157/id      		Historical; current review incomplete
      H51-8032CC6ED7726A0435FFD998first-look-v5.1.json
      /records/157/generic_name      		Historical; current review incomplete
      H51-64215BC5B44B45AB95ECED7Efirst-look-v5.1.json
      /records/157/class      		Historical; current review incomplete
      H51-77173BEE56BACCC6F6F5289Ffirst-look-v5.1.json
      /records/157/subclass      		Historical; current review incomplete
      H51-89616667F9AC4D7647E38878first-look-v5.1.json
      /records/157/primary_uses/0      		Historical; current review incomplete
      H51-46B5F2582466ED12DF4CAB54first-look-v5.1.json
      /records/157/primary_uses/1      		Historical; current review incomplete
      H51-5DB22A866A61FCAE35CCAB96first-look-v5.1.json
      /records/157/mechanism      		Historical; current review incomplete
      H51-1D595EC06BAEDD78D265760Cfirst-look-v5.1.json
      /records/157/mechanism_level      		Historical; current review incomplete
      H51-9325EEF2B14E735776111BCEfirst-look-v5.1.json
      /records/157/basic_dosing_orientation      		Historical; current review incomplete
      H51-0195C271E195D71A8DF4A111first-look-v5.1.json
      /records/157/administration_orientation      		Historical; current review incomplete
      H51-D03AAE9B1B35336A13D5AB9Dfirst-look-v5.1.json
      /records/157/renal_and_population_orientation      		Historical; current review incomplete
      H51-7B4BE5534520DDEA29D56859first-look-v5.1.json
      /records/157/key_safety_orientation/0      		Historical; current review incomplete
      H51-73C5DB2DE9D05644CE030700first-look-v5.1.json
      /records/157/key_safety_orientation/1      		Historical; current review incomplete
      H51-A2021BFEB02FED58939D82CFfirst-look-v5.1.json
      /records/157/coverage_path      		Historical; current review incomplete
      H51-5B1DC083F7A401C38A9D72C9first-look-v5.1.json
      /records/157/coverage_path_label      		Historical; current review incomplete
      H51-BC1F321633BA66D2A2DEA1D5first-look-v5.1.json
      /records/157/official_label_url      		Historical; current review incomplete
      H51-50950932D35B2B6C0BF9DDB5first-look-v5.1.json
      /records/157/legacy_title      		Historical; current review incomplete
      H51-A30C801220C7EF211F5D0890first-look-v5.1.json
      /records/157/review_note      		Historical; current review incomplete
      H51-F90E574DD5C7E8719B615814first-look-v5.1.json
      /records/157/search_text      		Historical; current review incomplete
      H51-BB12602BE3F08D7C80937EDEfirst-look-v5.1.json
      /records/157/official_search_url      		Historical; current review incomplete
      H51-76C25CBB2F67988883FB8171first-look-v5.1.json
      /records/157/official_access_mode      		Historical; current review incomplete
      H51-DFB4C2A406A14154DB38CCD1first-look-v5.1.json
      /records/157/official_access_url      		Historical; current review incomplete
      H51-A114779BE4710FE048521361first-look-v5.1.json
      /records/157/official_search_query      		Historical; current review incomplete
      H51-D9D1A6D1A6FB1720E480C4BAfirst-look-v5.1.json
      /records/157/official_access_reason      		Historical; current review incomplete
      H51-DF92A74FF7E8A1F174FCF997preparation-assessments-v3.8.json
      /157/id      		Historical; current review incomplete
      H51-C2254A67F572F72C4BC10E9Apreparation-assessments-v3.8.json
      /157/name      		Historical; current review incomplete
      H51-AD89DAA913BB4C8CF50295B9preparation-assessments-v3.8.json
      /157/brands      		Historical; current review incomplete
      H51-5A9BBCC311AB26D64D3D54ABpreparation-assessments-v3.8.json
      /157/therapeutic_class      		Historical; current review incomplete
      H51-3067DCD6B1BA9AF81AD27BC9preparation-assessments-v3.8.json
      /157/review_version      		Historical; current review incomplete
      H51-8C411FC2EE9F3E499E3F1D17preparation-assessments-v3.8.json
      /157/review_date      		Historical; current review incomplete
      H51-982A4825A90C6B15A8E8544Apreparation-assessments-v3.8.json
      /157/release_status      		Historical; current review incomplete
      H51-24BAF35D8AAB8FC853237FA2preparation-assessments-v3.8.json
      /157/market_status/status      		Historical; current review incomplete
      H51-003F8B12D18D7373243167ABpreparation-assessments-v3.8.json
      /157/market_status/basis      		Historical; current review incomplete
      H51-98B1D9458F988E71434A172Epreparation-assessments-v3.8.json
      /157/ten_point_assessment/exact_formulation      		Historical; current review incomplete
      H51-6D2FE7323FA3D31BD8EBBE96preparation-assessments-v3.8.json
      /157/ten_point_assessment/reconstitution_concentration      		Historical; current review incomplete
      H51-1EF8FB5A8638F198D392AF7Fpreparation-assessments-v3.8.json
      /157/ten_point_assessment/maximum_or_recommended_final_concentration      		Historical; current review incomplete
      H51-23ECAF8F8526DCDBA1423537preparation-assessments-v3.8.json
      /157/ten_point_assessment/appropriate_standardized_containers      		Historical; current review incomplete
      H51-742C0EEA4388B7207F3CA936preparation-assessments-v3.8.json
      /157/ten_point_assessment/adult_dosing_range      		Historical; current review incomplete
      H51-B4BC570705A2E6EBB7F76ED7preparation-assessments-v3.8.json
      /157/ten_point_assessment/pediatric_dosing_range      		Historical; current review incomplete
      H51-CD7D4ECBBFF2EC1F93AA84A3preparation-assessments-v3.8.json
      /157/ten_point_assessment/neonatal_dosing_range      		Historical; current review incomplete
      H51-F5CECB8C148A454B1E47D4A9preparation-assessments-v3.8.json
      /157/ten_point_assessment/infusion_time      		Historical; current review incomplete
      H51-0C933837B15351D36D55DBFEpreparation-assessments-v3.8.json
      /157/ten_point_assessment/fluid_restriction_alternatives      		Historical; current review incomplete
      H51-F2ADD0485F55FD3022935D1Cpreparation-assessments-v3.8.json
      /157/ten_point_assessment/current_manufacturer_labeling/setid      		Historical; current review incomplete
      H51-1937F5F06CFBF2A046CED899preparation-assessments-v3.8.json
      /157/ten_point_assessment/current_manufacturer_labeling/title      		Historical; current review incomplete
      H51-10E873541C6BC8942A2CA4C1preparation-assessments-v3.8.json
      /157/ten_point_assessment/current_manufacturer_labeling/published_date      		Historical; current review incomplete
      H51-F703F5565EBE6CEF24F774BApreparation-assessments-v3.8.json
      /157/ten_point_assessment/current_manufacturer_labeling/manufacturer      		Historical; current review incomplete
      H51-BD72C318723EBA3C80F1B9F7preparation-assessments-v3.8.json
      /157/ten_point_assessment/current_manufacturer_labeling/match_confidence      		Historical; current review incomplete
      H51-2D127D793D5AAC1A6F3B1E05preparation-assessments-v3.8.json
      /157/ten_point_assessment/current_manufacturer_labeling/url      		Historical; current review incomplete
      H51-1B2FBEC95E9023E9514F2CF8preparation-assessments-v3.8.json
      /157/field_provenance/exact_formulation/primary      		Historical; current review incomplete
      H51-C0C4839EEC3CBBECB29F5E33preparation-assessments-v3.8.json
      /157/field_provenance/reconstitution_concentration/primary      		Historical; current review incomplete
      H51-CE1D95C241C4782644594A88preparation-assessments-v3.8.json
      /157/field_provenance/maximum_or_recommended_final_concentration/primary      		Historical; current review incomplete
      H51-9AB5E8E09EF7C2DB5003FFFFpreparation-assessments-v3.8.json
      /157/field_provenance/appropriate_standardized_containers/primary      		Historical; current review incomplete
      H51-EF396E11E61C870FDDDBF689preparation-assessments-v3.8.json
      /157/field_provenance/adult_dosing_range/primary      		Historical; current review incomplete
      H51-C4982C228B3B5BF8687AAC53preparation-assessments-v3.8.json
      /157/field_provenance/pediatric_dosing_range/primary      		Historical; current review incomplete
      H51-6A7DA224F10A3E0921024D20preparation-assessments-v3.8.json
      /157/field_provenance/neonatal_dosing_range/primary      		Historical; current review incomplete
      H51-31FAE08A16EC4CAFC60CB950preparation-assessments-v3.8.json
      /157/field_provenance/infusion_time/primary      		Historical; current review incomplete
      H51-3121121914425918D461D772preparation-assessments-v3.8.json
      /157/field_provenance/fluid_restriction_alternatives/primary      		Historical; current review incomplete
      H51-B790DFC341587D5D62E9D831preparation-assessments-v3.8.json
      /157/field_provenance/current_manufacturer_labeling/primary      		Historical; current review incomplete
      H51-25B43E42AA8CD29AABC15BF5preparation-assessments-v3.8.json
      /157/population_applicability/adult/applicability      		Historical; current review incomplete
      H51-F48950553D0771FE5CFABEC8preparation-assessments-v3.8.json
      /157/population_applicability/adult/guide_generation_allowed      		Historical; current review incomplete
      H51-2E1B687CD03A4A3588B3D615preparation-assessments-v3.8.json
      /157/population_applicability/pediatric/applicability      		Historical; current review incomplete
      H51-73876D7451C81656F12B0958preparation-assessments-v3.8.json
      /157/population_applicability/pediatric/guide_generation_allowed      		Historical; current review incomplete
      H51-82580F8EF3F0EB451714AF5Cpreparation-assessments-v3.8.json
      /157/population_applicability/neonatal/applicability      		Historical; current review incomplete
      H51-B3DC748C877C7B7B38F267EEpreparation-assessments-v3.8.json
      /157/population_applicability/neonatal/guide_generation_allowed      		Historical; current review incomplete
      H51-2898240A4F62142D7CE7247Fpreparation-assessments-v3.8.json
      /157/route_presence/structured_dilution      		Historical; current review incomplete
      H51-78F0B4EF926BEB5B5A4FE60Apreparation-assessments-v3.8.json
      /157/route_presence/iv_push      		Historical; current review incomplete
      H51-27A043CAE884B314C3085C75preparation-assessments-v3.8.json
      /157/route_presence/continuous_infusion      		Historical; current review incomplete
      H51-0EC2452B11CE361EDE2AC236preparation-assessments-v3.8.json
      /157/route_presence/pediatric_source      		Historical; current review incomplete
      H51-350B91A44DB0E1309228348Cpreparation-assessments-v3.8.json
      /157/route_presence/neonatal_source      		Historical; current review incomplete
      H51-CB27435D85D724CF811F1024preparation-assessments-v3.8.json
      /157/legacy_reference/status      		Historical; current review incomplete
      H51-8EF628E132BC5F27496621E3preparation-assessments-v3.8.json
      /157/label_resolution/status      		Historical; current review incomplete
      H51-83245BA85F12FE2167753157preparation-assessments-v3.8.json
      /157/source_files/0      		Historical; current review incomplete
      H51-6CD4F33BA534365204177BC5preparation-assessments-v3.8.json
      /157/source_files/1      		Historical; current review incomplete
      H51-2510E4F5E2A9E0E7D26FF761preparation-assessments-v3.8.json
      /157/source_files/2      		Historical; current review incomplete
      H51-981B38C88E2623EDCEB49C29preparation-assessments-v3.8.json
      /157/clinical_release_note      		Historical; current review incomplete

      Open the original GlobalRPh site monograph (historical; not revalidated) (opens in a new tab)

      All medicationsReturn to medication headingApplication top